Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Facts Label Should Be Required On Immediate Package – ONP’s Ganley

This article was originally published in The Tan Sheet

Executive Summary

Allowing the sale of OTC drugs in packages without Drug Facts labels on the immediate container poses risks for consumers, FDA Office of Nonprescription Products Director Charles Ganley says

You may also be interested in...



FDA Will Cooperate With OTC Drug Industry To Address Labeling Questions

FDA will work cooperatively with industry to address complications that may arise from the final rule on standardized OTC labeling announced March 11, Commissioner Jane Henney, MD, told the Nonprescription Drug Manufacturers Association annual meeting in Boca Raton, Fla. March 12 (see related stories, pp. 4-10). NDMA is being renamed the Consumer Healthcare Products Association.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

In US, Market Exclusivity For NDI Notifications ‘Just Not There’ In DSHEA Regulation

Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel